Roche’s deep discount for MS drug Ocrevus pays off big for Swiss drugmaker
admin 27th July 2017 Uncategorised 0Roche caught the market by surprise when it priced its highly touted new multiple sclerosis drug Ocrevus at a 25% discount to the competition. Roche’s gambit has surprised again, with Ocrevus winning immediate uptake and generating $200 million in its first quarter on the market.
More: Roche’s deep discount for MS drug Ocrevus pays off big for Swiss drugmaker
Source: fierce